Details of the Drug

General Information of Drug (ID: DMWCXPK)

Drug Name

Haloperidol

Synonyms

Haldol; Aloperidin; Serenace; Aloperidol; Eukystol; Brotopon; Einalon S; Ulcolind; Serenase; Uliolind; Serenelfi; Aloperidolo; Vesalium; Halopoidol; Galoperidol; Halojust; Pernox; Mixidol; Halopal; Linton; Sernel; Sernas; Dozic; Aldo; Lealgin compositum; Keselan; Peluces; Bioperidolo; Haldol Solutab; McN-JR-1625; Haloperidolum; Aloperidon; Fortunan; Aloperidolo [DCIT]; Aloperidolo [Italian]; Haloperidolum [INN-Latin]

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

375.9

Topological Polar Surface Area (xlogp)

3.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.7-6.1 h [3]
Clearance: The clearance of drug is 0.39-0.708 L/h/kg [3]
Elimination: In radiolabeling studies, approximately 30% of the radioactivity is excreted in the urine following a single oral administration of 14C-labelled haloperidol, while 18% is excreted in the urine as haloperidol glucuronide, demonstrating that haloperidol glucuronide is a major metabolite in the urine as well as in plasma in humans [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 14.5 - 36.7 hours [3]
Metabolism: The drug is metabolized via the liver [3]
Vd: The volume of distribution (Vd) of drug is 9.5-21.7 L/kg [3]

Chemical Identifiers

Formula: C21H23ClFNO2
IUPAC Name: 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
Canonical SMILES: C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
InChI: InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
InChIKey: LNEPOXFFQSENCJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3559
ChEBI ID: CHEBI:5613
CAS Number: 52-86-8
DrugBank ID: DB00502
TTD ID: D0A6NU
ACDINA ID: D00310

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN opioid receptor sigma 1 (OPRS1)	TTTPE1L	SGMR1_HUMAN	Modulator	[4]
HUMAN sigma intracellular receptor 2 (TMEM97)	TTIS0R2	SGMR2_HUMAN	Modulator	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076035.
2	Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25.
3	Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999 Dec;37(6):435-56. doi: 10.2165/00003088-199937060-00001.
4	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing